Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protagonist Therapeutics (PTGX) EBITDA (2017 - 2025)

Historic EBITDA for Protagonist Therapeutics (PTGX) over the last 9 years, with Q3 2025 value amounting to -$46.4 million.

  • Protagonist Therapeutics' EBITDA fell 1198.47% to -$46.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.0 million, marking a year-over-year decrease of 8725.25%. This contributed to the annual value of $252.8 million for FY2024, which is 36998.14% up from last year.
  • Per Protagonist Therapeutics' latest filing, its EBITDA stood at -$46.4 million for Q3 2025, which was down 1198.47% from -$42.0 million recorded in Q2 2025.
  • In the past 5 years, Protagonist Therapeutics' EBITDA ranged from a high of $206.3 million in Q1 2024 and a low of -$46.4 million during Q3 2025
  • In the last 5 years, Protagonist Therapeutics' EBITDA had a median value of -$36.0 million in 2023 and averaged -$10.8 million.
  • Its EBITDA has fluctuated over the past 5 years, first tumbled by 33651.57% in 2021, then surged by 67274.65% in 2024.
  • Protagonist Therapeutics' EBITDA (Quarter) stood at -$37.0 million in 2021, then rose by 1.35% to -$36.5 million in 2022, then surged by 163.12% to $23.0 million in 2023, then surged by 450.05% to $126.8 million in 2024, then plummeted by 136.62% to -$46.4 million in 2025.
  • Its EBITDA stands at -$46.4 million for Q3 2025, versus -$42.0 million for Q2 2025 and -$19.3 million for Q1 2025.